bb 2121

Drug Profile

bb 2121

Alternative Names: Anti-BCMA CAR T cells - bluebird bio/Celgene; BB-2121; bb2121

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator bluebird bio
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action B-cell maturation antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 30 Nov 2016 Interim efficacy and adverse events data from the phase I CRB-401 trial in Multiple myeloma (Second-line therapy or greater) released by bluebird bio
  • 31 May 2016 BB 2121 receives Orphan Drug status for Multiple myeloma in USA
  • 01 Apr 2016 bluebird bio initiates a follow-up clinical trial for Multiple myeloma (Second-line therapy or greater) in USA (IV) (NCT02786511)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top